Pro-Dex, Inc.

Pro-Dex, Inc. (PDEX) Market Cap

Pro-Dex, Inc. has a market capitalization of $187M.

Price: $58.57

β–² 1.92 (3.39%)

Market Cap: 187.00M

NASDAQ Β· time unavailable

CEO: Richard Lee Van Kirk Jr.

Sector: Healthcare

Industry: Medical - Instruments & Supplies

IPO Date: 1986-08-07

Website: https://www.pro-dex.com

Pro-Dex, Inc. (PDEX) - Company Information

Market Cap: 187.00M|Sector: Healthcare

Company Profile

Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio features versatile, autoclavable (sterilization-friendly) surgical drivers and shavers, available in both battery-powered and electric models, often equipped with multi-functional capabilities. These instruments are primarily employed in orthopedic, thoracic, and craniomaxillofacial surgical procedures. Beyond its core manufacturing, Pro-Dex also offers expert consulting services, covering engineering, quality assurance, and regulatory compliance. Furthermore, the company manufactures and distributes rotary air motors to various industrial clients. Founded in 1978, Pro-Dex, Inc. maintains its corporate headquarters in Irvine, California.

Analyst Sentiment

83%
Strong Buy

From 1 Active Polls

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$61.50
β–² +5.00% Upside
Low Target
$43.93
-25% Risk
Median Target
$59.74
2% Mid
High Target
$73.21
25% Max
Consensus
Buy
1 / 1 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

πŸ“Š Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1871571251101421621529762
Enterprise Value ($M)19716712912415817717010973
Price to Earnings Ratio (P/E)15.839.9814.365.9229.4912.3918.559.829.76
Price/Earnings-to-Growth Ratio (PEG)β€”1.4520.001.0064.183.351.45β€”1.91
Price to Sales Ratio (P/S)2.517.886.705.968.139.289.086.534.15
Price to Book Ratio (P/B)4.153.483.002.663.884.584.793.152.02
Price to Free Cash Flow Ratio (P/FCF)26.83103.3935.7049.91-535.01281.68-32.4966.8368.35
Enterprise Value to Sales (EV/Sales)β€”8.396.916.689.0610.1510.137.344.88
Enterprise Value to EBITDA (EV/EBITDA)10.0428.3638.1118.3743.9038.2854.8528.9530.74
Debt to Equity Ratio0.520.450.280.330.450.560.560.490.44

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ PRO DEX INC (PDEX) β€” Investment Overview

🧩 Business Model Overview

PRO DEX Inc operates as a niche manufacturing and engineering supplier of high-reliability, custom electromechanical and electronics components/assemblies for demanding end markets such as defense/aerospace and other mission-critical applications. The value chain centers on (1) customer-specific design/engineering support, (2) qualification and certification of parts and processes, and (3) recurring production and supply for qualified programs. After qualification, the company typically benefits from repeat ordering, incremental engineering changes, and long customer evaluation/renewal cycles that make supplier replacement difficult.

πŸ’° Revenue Streams & Monetisation Model

Revenue is primarily driven by program-based and customer-based production orders, supported by engineering-enabled repeat business. Monetisation is a blend of transactional manufacturing (units/assemblies delivered against demand) and quasi-recurring cash flows (reorders tied to ongoing program utilization and engineering change orders). Margin structure typically hinges on:

  • Pricing power tied to qualification status (ability to price for compliance, reliability, and validated production processes)
  • Mix and complexity (higher complexity assemblies and integration work tend to carry better contribution margins)
  • Manufacturing yield and throughput (precision process control reduces scrap/rework)
  • Program duration and backlog conversion (stable production schedules smooth utilization and fixed-cost absorption)

🧠 Competitive Advantages & Market Positioning

PRO DEX’s competitive position is best understood through switching costs and intangible, qualification-based assets rather than broad brand or mass-market scale.

  • Switching Costs (Qualification & Compliance): Mission-critical customers require supplier qualification, validated processes, and documented quality systems. Once approved for a program, replacing the supplier typically involves engineering re-validation, new testing/qualification, and schedule riskβ€”costs that favor incumbents.
  • Intangible Assets (Process Know-How & Customer Engineering): Engineering collaboration and production discipline build durable operational learning curves, reflected in yield, reliability, and responsiveness to change orders.

Competitive benchmarking:

  • Sanmina and Celestica (large EMS/solution integrators): operate at materially greater scale and breadth across end markets. Their advantage is supply-chain scale and wide customer coverage, while PRO DEX typically competes by being closer to specific, high-reliability engineering/manufacturing requirements.
  • Benchmark Electronics (diversified electronics manufacturing): competes on engineering and manufacturing services across industries. PRO DEX’s industry focus and emphasis on qualification-intensive, custom production can create stronger customer stickiness where program approval cycles matter more than broad volume capability.

πŸš€ Multi-Year Growth Drivers

Over a five- to ten-year horizon, PRO DEX’s growth outlook depends less on broad cyclical volume and more on secular demand for mission-critical electronics and the ongoing outsourcing of specialized manufacturing. Key drivers include:

  • Defense and aerospace electronics content per platform: platform modernization and system complexity tend to increase the value of qualified components and assemblies.
  • Supplier qualification and compliance outsourcing: customers increasingly prefer specialized suppliers that can demonstrate repeatability, documentation, and test rigor.
  • Program refresh cycles and engineering change orders: ongoing lifecycle support (including revisions) can extend demand beyond initial production runs.
  • Reliability-driven procurement: higher reliability requirements favor suppliers with proven manufacturing discipline and validated quality systems.

⚠ Risk Factors to Monitor

  • Customer/program concentration risk: revenue can be sensitive to timing and scope of specific customer programs or budget allocations.
  • Qualification and acceptance lead times: new business can face delays due to testing, qualification, and documentation requirements.
  • Supply chain and input cost volatility: precision manufacturing can be exposed to component availability and cost swings.
  • Technological shifts: changes in platform architectures, materials, or electronic design norms can require process updates and engineering investment.
  • Working capital and fixed-cost absorption: utilization swings from demand timing can pressure margins if capacity planning is not aligned.
  • Regulatory/export constraints: defense-related compliance and export controls can affect customer mix and product delivery pathways.

πŸ“Š Valuation & Market View

Markets typically value electronics manufacturing and defense-supply businesses using EV/EBITDA, EV/Sales (where earnings quality is variable), and cash flow yield, with attention to margin sustainability and backlog/order visibility. The primary valuation drivers tend to be:

  • Durability of margins (evidence of stable yield, pricing discipline, and favorable mix)
  • Quality of demand (program stability vs. purely commodity-like orders)
  • Execution consistency (on-time delivery, low defect rates, and smooth conversion of orders into cash)
  • Reinvestment needs (capex and engineering spending required to sustain qualification and capacity)

When investors perceive improved repeatability in customer qualification outcomes and stronger conversion of work into cash, valuation multiples generally expand; conversely, margin compression or program churn can reduce them.

πŸ” Investment Takeaway

PRO DEX’s long-term investment case rests on qualification-driven switching costs and embedded manufacturing and engineering know-how that support customer stickiness in mission-critical markets. The moat is not scale or brandβ€”it is the difficulty of replacing a supplier once processes and acceptance criteria are validated. With demand supported by defense/aerospace system complexity and ongoing lifecycle engineering needs, the central question for investors is whether the company can sustain margins and cash conversion through program cycles while managing qualification, input costs, and execution risk.


⚠ AI-generated β€” informational only. Validate using filings before investing.

πŸ“° Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for PDEX.

seekingalpha.comβ€’2026-05-15

Pro-Dex: Still A Buy, But Don't Chase

Pro-Dex reported nice Q1 sales of $19.9 million, which is up 14.6% YoY. Their largest customer contract now runs through December 2028, reducing potential near-term risks in that sense. Also, their APM acquisition gives them more control over their supply chain and brings some potential aerospace/defense optionality.

accessnewswire.comβ€’2026-04-30

Pro-Dex, Inc. Announces Fiscal 2026 Third Quarter and Nine Month Results

IRVINE, CA / ACCESS Newswire / April 30, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 third quarter ended March 31, 2026.

defenseworld.netβ€’2026-03-28

Pro-Dex (NASDAQ:PDEX) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

Shares of Pro-Dex, Inc. (NASDAQ: PDEX - Get Free Report) passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $38.09 and traded as high as $50.06. Pro-Dex shares last traded at $48.98, with a volume of 30,677 shares traded. Wall Street Analyst

accessnewswire.comβ€’2026-02-12

Pro-Dex, Inc. Announces Acquisition of Advanced Precision Machining

IRVINE, CA / ACCESS Newswire / February 12, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced that on February 9, 2026 it completed its acquisition of Advanced Precision Machining LLC, ("APM"), formerly operated as Advanced Precision Machining, Inc., a manufacturing facility located in Costa Mesa, Calif.

accessnewswire.comβ€’2026-01-29

Pro-Dex, Inc. Announces Fiscal 2026 Second Quarter and Six-Month Results

IRVINE, CA / ACCESS Newswire / January 29, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 second quarter ended December 31, 2025.

defenseworld.netβ€’2026-01-28

Head-To-Head Contrast: Pro-Dex (NASDAQ:PDEX) vs. STAAR Surgical (NASDAQ:STAA)

Pro-Dex (NASDAQ: PDEX - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Profitability This table compares Pro-Dex and STAAR Surgical's

seekingalpha.comβ€’2026-01-17

Pro-Dex: A Niche Surgical Tools Microcap Trading At A Discount

Pro-Dex manufactures powered surgical instruments for orthopedic, CMF, and thoracic procedures. This means that PDEX effectively combines OEM programs with a smaller catalog of industrial offerings. However, PDEX's revenue today remains highly concentrated. A single customer drives roughly 78% of sales.

defenseworld.netβ€’2026-01-12

D.A. Davidson & CO. Increases Holdings in Pro-Dex, Inc. $PDEX

D.A. Davidson and CO. boosted its stake in Pro-Dex, Inc. (NASDAQ: PDEX) by 152.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,073 shares of the medical instruments supplier's stock after purchasing an additional 15,738 shares during

seekingalpha.comβ€’2026-01-08

Pro-Dex Valuation Is Attractive Despite Customer Risk

Pro-Dex Inc. is a specialized surgical device manufacturer with strong growth, efficient capital allocation, and high customer concentration risk. PDEX trades at ~16x recurrent earnings, which is fair and attractive for a small, non-concentrated position given its quality and growth prospects. Customer concentration remains the key risk, but contract renewals, sticky relationships, and secular healthcare tailwinds support continued growth.

defenseworld.netβ€’2026-01-05

Head to Head Survey: Cardinal Health (NYSE:CAH) vs. Pro-Dex (NASDAQ:PDEX)

Cardinal Health (NYSE: CAH - Get Free Report) and Pro-Dex (NASDAQ: PDEX - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership. Profitability This table compares Cardinal Health and Pro-Dex's net

defenseworld.netβ€’2025-12-28

Head-To-Head Review: Pro-Dex (NASDAQ:PDEX) & Spotlight Innovation (OTCMKTS:STLT)

Pro-Dex (NASDAQ: PDEX - Get Free Report) and Spotlight Innovation (OTCMKTS:STLT - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations. Profitability This table compares Pro-Dex and Spotlight Innovation's net

accessnewswire.comβ€’2025-12-19

Pro-Dex, Inc. Announces Contract Extension With Largest Customer

IRVINE, CA / ACCESS Newswire / December 19, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced that on December 17, 2025, it executed a contract amendment with its largest customer for an additional three years.

defenseworld.netβ€’2025-12-12

Head to Head Contrast: Spotlight Innovation (OTCMKTS:STLT) versus Pro-Dex (NASDAQ:PDEX)

Spotlight Innovation (OTCMKTS:STLT - Get Free Report) and Pro-Dex (NASDAQ: PDEX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations. Valuation and Earnings This table compares Spotlight Innovation and

defenseworld.netβ€’2025-11-18

Head to Head Review: Pro-Dex (NASDAQ:PDEX) vs. Lifevantage (NASDAQ:LFVN)

Lifevantage (NASDAQ: LFVN - Get Free Report) and Pro-Dex (NASDAQ: PDEX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Profitability This table compares Lifevantage and Pro-Dex's net margins,

zacks.comβ€’2025-10-30

Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Top Estimates

Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.75 per share a year ago.

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"PDEX reported Q3’26 (ended 2026-03-31) revenue of $19.95M and net income of $3.94M, for EPS of $1.23 (diluted $1.20). Versus the prior quarter (QoQ), revenue rose +6.9% (from $18.66M) and net income surged +80.0% (from $2.19M). Versus the same quarter last year (YoY), revenue increased +14.6% (from $17.41M) and net income grew +20.2% (from $3.28M). Profitability improved: net margin expanded to 19.7% from 11.7% QoQ and from 18.8% YoY. Gross margin was steady to slightly lower QoQ (30.7% vs 30.8%) but far higher than Q4’25’s low (19.9%), indicating normalization from a weaker quarter. Cash generation was solid this quarter: operating cash flow was $1.63M, turning into positive free cash flow of $1.70M (after only modest CapEx). The balance sheet remains liquid with cash & equivalents of $10.0M and total assets of $75.0M; equity increased to $45.2M from $41.6M QoQ. Total debt declined sequentially to $19.3M, and leverage improved. Total shareholder returns look mixed based on available market data: the stock is up strongly over 6 months (+123%) and YTD (+41.6%) but down over 1 year (-12.9%). With no dividends and no explicit buyback/capital return trend stated beyond one-quarter repurchases, shareholder value appears primarily momentum-driven rather than yield-driven."

Revenue Growth

Good

Revenue increased +6.9% QoQ and +14.6% YoY, with an overall upward trajectory after weaker Q4’25 results.

Profitability

Strong

Net income rose +80.0% QoQ and +20.2% YoY; net margin expanded to 19.7% from 11.7% QoQ (and ~flat YoY vs 18.8%).

Cash Flow Quality

Positive

Operating cash flow was positive ($1.63M) and free cash flow was positive ($1.70M). However, cash flow has been volatile across recent quarters.

Leverage & Balance Sheet

Good

Total assets and equity strengthened QoQ; total debt declined to $19.3M. Liquidity remains strong with ~$10.0M cash and cash equivalents.

Shareholder Returns

Neutral

No dividend yield (0). Total return is likely supported by price momentum (+123% 6M, +41.6% YTD), but 1Y is negative (-12.9%).

Analyst Sentiment & Valuation

Neutral

Valuation metrics indicate elevated multiples (e.g., P/E ~10.0 using provided ratio set), but analyst price target data is not provided (no target vs current).

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So what: Q1 FY2015 showed relatively flat top-line growth ($2.6M, +2% YoY) driven by a rebound in the largest customer (+$400k), but profitability deteriorated sharply. Gross margin fell to 32% from 37% (down 5 pts) as management pointed to lower-margin product mix versus repairs, plus higher accruals for anticipated losses on fixed-price development contracts and under-absorbed manufacturing costs. The analyst-style pressure in the Q&A focused less on accounting and more on timing: management reiterated products are in final testing and should move into manufacturing/shipment within the fiscal year, while acknowledging that testing is lengthy. On capital return, a shareholder asked about buyback scope: management confirmed ~41k shares repurchased so far and that the $750k board-approved authorization is not yet being fully pursued. Overall tone is constructive (customer frames, engineering services launch), but the hard numbers show execution/profitability headwinds remain immediate.

AI IconGrowth Catalysts

  • Resumption of product shipments to the largest medical customer (after suspension March–November 2013) and expected follow-on frame contracts
  • Engineering Services Division launch (engineering consulting and placement services) expected to add revenue and create business-development synergies

Business Development

  • Largest medical company customer: resumption of shipments in December 2013 and receipt of follow-on frame contracts
  • Engineering Services Division target: placement/contract engineer services and potential consulting from in-house staff (prospects via shared engineering/contact base, incl. GM Marvin Gidney and VP of Engineering)

AI IconFinancial Highlights

  • Net sales: $2.6M, +2% YoY ($2.5M prior year). Underlying drivers: +$400k sales to largest customer; -$183k repair revenue from former largest medical device customer; -$151k sales to another customer
  • Gross profit: $828k, down $117k (-12%) YoY; gross margin % declined to 32% from 37% (down 5 percentage points)
  • Gross margin headwinds: product mix shift (less high-margin repairs, more lower-margin product sales), higher accruals for anticipated losses on fixed-price product development services, and under-absorbed manufacturing costs from reduced volumes
  • Partially offset: lower inventory and warranty charges due to downward revision in estimated per-unit repair costs
  • Operating expenses: +10% to $1.0M YoY (primarily business development expense increases and project-related legal costs)
  • Operating results: loss from continuing operations -$181k vs income +$18k prior year; net loss -$170k (-$0.04/share) vs net income $212k (+$0.06/share) prior year (prior-year net income included $167k gain on sale of Carson City facility in discontinued ops)

AI IconCapital Funding

  • Share repurchase activity disclosed in Q&A: ~41,000 shares repurchased so far (Q&A)
  • Board-approved repurchase plan referenced: $750,000 total approved a year ago, but management stated current repurchase plan is not for the entire amount and details were not disclosed

AI IconStrategy & Ops

  • Product development projects: management characterized them as in final phase of testing; still expects manufacturing and product shipment phase to begin within fiscal 2015 (timeline remained contingent on a 'lengthy' testing phase)
  • New Engineering Services Division launched: aims to use internal engineering talent and shared contact base to sell a menu of services (placement of engineers on contract basis and potential consulting)

AI IconMarket Outlook

  • Management maintained outlook: product shipments expected within the current fiscal year (Q&A)
  • Next earnings timing: expects to report fiscal year 2015 Q2 and first half results in February (closing remarks)

AI IconRisks & Headwinds

  • Operational profitability pressure from lower-margin mix: repairs (higher gross margin) vs product sales (lower gross margin) following resumption of product shipments
  • Fixed-price development services risk: increased accruals for anticipated losses on certain contracts
  • Manufacturing inefficiency risk: under-absorbed manufacturing costs tied to reduced volumes
  • Product development testing remains a pacing constraint: final testing phase described as 'lengthy' with ongoing execution risk
  • Tax/NOL risk mitigated in Q&A: management stated no issues with tax implications on net operating losses

Sentiment: MIXED

Note: This summary was synthesized by AI from the PDEX Q1 2015 (ended September 30, 2014) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

πŸ“‹ Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for PDEX.

SEC EDGAR Live Feed
Loading financial data and tables...
πŸ“

SEC Filings (PDEX)

Β© 2026 Stock Market Info β€” Pro-Dex, Inc. (PDEX) Financial Profile